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Introduction: Cardiac-derived c-kit+ precursor cells (CPCs) and bone marrow-derived mesenchymal stem cells (MSCs) are both in clinical trials, 
but the relative therapeutic efficacy of these two cell types is unknown. We tested the hypothesis that human CPCs have greater potency than MSCs 
in cardiac repair.
Methods:  We compared intramyocardial injection of human fetal CPC’s (36,000, n=14) with two doses of adult MSCs (36,000: n=16 and 1 
million, n=10) or control (PBS, n=17) in NOD/SCID mice immediately after permanent LAD ligation. Serial echocardiographies were performed over 
8 weeks followed by pressure volume (PV) loop and immunohistological evaluation.
Results:  Myocardial infarction (MI) caused a time dependent increase of end diastolic volume in the control group from 28±1μl (baseline) to 
129±17μl, which improved in the CPC treated (101±14μl, P<0.05) but not in the high- (118±17μl) or low-dose (133±14μl) MSC groups.
The ejection fraction decrease in the control group (73±4% to 18±5%), improved with CPCs (32±6%) or high dose MSCs (23±3%, P<0.05, vs. 
control for both) but not low dose MSCs (18±4%). PV loop analysis showed improved systolic function in CPC treated hearts: Preload recruitable 
stroke work: 49±6mmHg vs. 32±7mmHg in control, 26±5mmHg in high dose MSCs and 21±5mmHg in low dose (P<0.05). Using human specific 
(Alu) DNA sequence, CPCs had higher engraftment (30.3±4.5 cell/mm2) than either of the MSC doses (high: 0.7±0.1 cell/mm2, p=0.0006, low 
<0.01 cells/mm2). A large percentage of CPCs showed both cardiomyocyte or vascular differentiation as indicated by their co-staining for troponin I, 
_-sarcomeric actin and connexin43, whereas MSCs preferentially formed vascular structures or remained undifferentiated.
Conclusion: These data demonstrate that CPCs exhibit an enhanced ability to engraft, differentiate, and improve cardiac remodeling and function 
in ischemic heart failure than MSCs. A 30-fold greater dose of MSCs failed to improve cardiac function and anatomy better than CPCs. Together these 
findings demonstrate, in a rigorous head to head comparison, the superiority of c-kit CPCs as a regenerative cell-based therapeutic for cardiac repair 
after infarction.
